Biogen Inc

NASDAQ:BIIB   3:59:52 PM EDT
337.92
+6.22 (+1.88%)
Products, Other Pre-Announcement

Biogen Sees FY2021 Non-GAAP Diluted EPS $17.50 To $19.00

Published: 07/22/2021 11:19 GMT
Biogen Inc (BIIB) - Biogen Reports Second Quarter 2021 Results.
Qtrly GAAP Diluted EPS $2.99; Non-GAAP Diluted EPS $5.68.
Biogen - Second Quarter Revenue $2,775 Million.
Qtrly Aduhelm™ Revenue Was $2 Million.
Biogen - Sees FY 2021 Total Revenue $10.65 to $10.85 Billion.
Biogen - Sees FY 2021 Non-GAAP Diluted EPS $17.50 to $19.00.
Qtrly Tecfidera Revenue of $487.6 Million Versus $1,181.6 Million Reported Last Year.
Biogen - 2021 Non-GAAP Research and Development Expense is Expected to Be Between $2.45 Billion and $2.55 Billion.
Q2 Earnings per Share View $4.54, Revenue View $2.60 Billion -- Refinitiv Ibes Data (analyst estimates).
Qtrly Spinraza Revenue of $499.7 Million Versus $494.6 Million Reported Last Year.
FY2021 Earnings per Share View $18.61, Revenue View $10.64 Billion -- Refinitiv Ibes Data (analyst estimates).
Further Company Coverage: .
((reuters.
Briefs@thomsonreuters.
Com;)).